Differential Metabolic Effects of Fenofibrate and Fatty Acid

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01003847

Enrollment

150

Registered

2009-10-29

Start date

2009-11-30

Completion date

2010-09-30

Last updated

2011-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertriglyceridemia

Keywords

Insulin resistance

Brief summary

The investigators hypothesize that fenofibrate and fatty acid may have different metabolic effects in hypertriglyceridemic patients

Interventions

DRUGfenofibrate, fatty acid, placebo

fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

25 Years to 75 Years

Healthy volunteers

Inclusion criteria

* hypertriglyceridemia

Exclusion criteria

* Overt liver disease Chronic renal failure Hypothyroidism Myopathy Uncontrolled diabetes Severe hypertension

Design outcomes

Primary

Measure	Time frame
flow-mediated dilation	8 weeks of treatment

Secondary

Measure	Time frame
insulin resistance	8 weeks of treatment

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026